FDA Approves Rasonque After the Pan-RAS Wager Pays Off

The FDA approved Rasonque on August 26, 2026, a once-daily pill that cut the risk of death by 60% in metastatic pancreatic cancer. Revolution Medicines’ daraxonrasib is the first medicine cleared to block the RAS proteins that drive more than 90% of these tumors, and patients on the pill lived a median of 13.2 months versus 6.7 months on chemotherapy.

That result is the payout on a scientific wager most of the field sidestepped. Earlier RAS drugs locked onto a G12C mutation that barely shows up in the pancreas, while this pill was built to hit the mutations that actually run the disease.

RASolute 302 Cut Deaths by 60 Percent

The FDA approved daraxonrasib for metastatic pancreatic adenocarcinoma in adults who have already had at least one systemic therapy, or who cannot take combination chemotherapy. Efficacy came from RASolute 302, a 500-person randomized trial (248 on daraxonrasib, 252 on physician-choice chemotherapy) after one prior line of treatment.

Median overall survival in the full trial was 13.2 months on the pill and 6.7 months on chemotherapy, a hazard ratio of 0.40. Median progression-free survival was 7.2 months versus 3.6 months. The share of patients with a measurable response was 30% versus 11%. All three gaps were statistically significant, the agency said, in both the RAS G12 group and the overall population.

The New England Journal of Medicine report on the same trial put median survival in the RAS G12 group at 13.2 months versus 6.6 months on chemotherapy, and said 91.8% of the 500 patients had a RAS G12 mutation. Treatment-related events that forced a stop occurred in 1.2% of the daraxonrasib group and 11.2% of the chemotherapy group, the journal said.

Revolution Medicines also reported patient-scored results that the FDA write-up did not list. Time to a drop in global health status was 5.7 months on the pill versus 2.6 months on chemotherapy, and time to worsening pain was 9.2 months versus 3.8 months, according to the company’s approval release. The recommended dose is 300 mg by mouth once a day until the cancer grows or the side effects cannot be managed.

At the American Society of Clinical Oncology meeting in May, where the survival curves were first shown in public, Mark Lewis, a gastrointestinal oncologist at Intermountain Health, wrote that the hall answered with cheers and a standing ovation, adding that it felt as if “ras targeting has arrived.”

Why G12C Pills Never Reached Pancreatic Tumors

Amgen’s sotorasib and Mirati’s adagrasib, now under Bristol Myers Squibb, proved a RAS protein could be drugged, but they were built for KRAS G12C, a change that is common in lung cancer and rare in the pancreas. A review in Cancer Discovery puts KRAS mutations in about 99% of pancreatic ductal adenocarcinomas and lists G12D, G12V and G12R as the dominant changes, at about 41%, 32% and 16%. G12C accounts for less than 2% of cases, so the first RAS pills were aimed at a slice of pancreatic cancer that almost never walks into clinic.

When sotorasib was tried in that tiny G12C pancreatic group, CodeBreaK 100 recorded an objective response in 21% of 38 patients and a median overall survival of 6.9 months, according to published summaries of that study. Adagrasib’s KRYSTAL-1 pancreatic cohort reported a median overall survival of 8 months. Those numbers sit in the same range as the chemotherapy arm of RASolute 302, which is the point of the mutation math: a G12C pill cannot be a pancreatic cancer drug if G12C is a 1% event.

G12R is an even colder target for the older design. The arginine side chain crowds the switch II pocket that G12C covalent drugs use, which is why allele-specific programs have struggled there. A pan-RAS binder that does not depend on that cysteine handle was the only way to cover G12D, G12V and G12R with one pill, and that is the bet Revolution Medicines placed.

A Molecular Glue for the On Switch

Daraxonrasib, first coded RMC-6236, does not try to occupy a classic drug pocket on RAS. It binds the chaperone protein cyclophilin A, reshapes that protein’s surface, and forms a three-part complex that grabs RAS in its GTP-bound “on” state, blocking the downstream partners the tumor needs. The chemistry traces to a Warp Drive Bio glue platform that Revolution Medicines bought in 2018, then widened from a G12C-only covalent probe into a noncovalent, multi-selective pill that hits mutant and wild-type KRAS, NRAS and HRAS.

That on-state choice matters in pancreatic cancer because the common KRAS mutants spend most of their time locked on. G12C drugs that prefer the inactive GDP form leave a gap those tumors can walk through. The glue was meant to close it.

For the first time, patients have an approved targeted medicine designed to directly inhibit the main cause of pancreatic cancer, RAS, which has been one of the most intractable disease targets since its discovery decades ago.

Mark A. Goldsmith, M.D., Ph.D., chief executive, Revolution Medicines

Brian M. Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute and the RASolute 302 principal investigator, said physicians have for decades relied on intravenous chemotherapy even though RAS is the main driver, and that this approval gives them “confidence that directly inhibiting RAS can make a striking difference for patients.” The American Cancer Society estimates about 67,530 people will be diagnosed with pancreatic cancer in the United States in 2026, and about 52,740 will die of it, about 3% of new cancers and about 8% of cancer deaths.

How Broad Is the Rasonque Label?

The approved use covers adults with metastatic pancreatic adenocarcinoma after at least one systemic therapy, and adults who are not candidates for combination chemotherapy, with no required KRAS allele, no required prior regimen, and no companion diagnostic. Revolution Medicines said the nod applies with or without an identified RAS tumor mutation and does not require a companion diagnostic test. That is a disease-level label on a molecular drug, written after a survival benefit large enough that regulators did not fence it off by allele.

WHAT THE LABEL ALLOWS

• Prior therapy: At least one prior systemic treatment, or inability to take combination chemotherapy.
• Mutation test: None required, and no specified KRAS allele.
• Companion diagnostic: Not part of the approval.
• Dose: 300 mg orally once daily, sold as tablets, now available by prescription in the United States.

Neil Vasan, a physician-scientist at NYU Langone who previously served as acting chair of the FDA’s Oncologic Drugs Advisory Committee, argued the morning after the nod that precision oncology has trained doctors to match “mutation X” to “drug Y,” and that this label does something else. The “not candidates for multiagent systemic therapy” clause, he noted, can pull the pill earlier for patients who cannot tolerate combination chemotherapy, which is a wider door than a classic second-line targeted-therapy indication.

The file moved on a stack of FDA shortcuts. Daraxonrasib had Breakthrough Therapy and Orphan Drug designations, went through Real-Time Oncology Review, and was part of the Commissioner’s National Priority Voucher pilot, which is meant to compress review toward one to two months. The agency said it approved the application about 6.5 months ahead of its goal date. The review also ran under Project Orbis with Health Canada; the European Medicines Agency and Japan’s PDMA sat as observers.

PATH TO THE NOD

1. June 23, 2025: FDA grants Breakthrough Therapy designation for previously treated metastatic pancreatic cancer with KRAS G12 mutations.
2. April 13, 2026: Revolution Medicines reports the Phase 3 survival result.
3. April 26, 2026: Former Sen. Ben Sasse describes the drug on CBS’s 60 Minutes.
4. May 1, 2026: FDA clears an expanded-access protocol two days after the company asked.
5. July 22, 2026: The agency accepts the new drug application.
6. August 26, 2026: Rasonque is approved, more than six months ahead of the user-fee goal date.

Sasse, a former Republican senator from Nebraska, was diagnosed with stage 4 pancreatic cancer in December 2025 and joined a trial. He told Scott Pelley he had “much, much less pain than I had four months ago when I was diagnosed” and “a massive 76% reduction in tumor volume over the last four months.” The public run-up, including that interview, is what the company and the FDA have tied to the May expanded-access letter. Acting FDA Commissioner Kyle Diamantas said it is the agency’s “fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.”

Rash, Mouth Sores and a $39,800 Month

The prescribing information warns about skin and soft-tissue toxicity, mouth sores, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and harm to a fetus. The company’s list of reactions seen in at least 20% of patients is rash, diarrhea, stomatitis, nausea, vomiting, abdominal pain, edema, decreased appetite and hemorrhage. Sasse’s on-camera face rash is the side effect patients already recognize from the spring interviews.

LABEL WARNINGS

• Skin and tissue: Dermatologic and soft-tissue toxicity, with rash the most common reason for a pause.
• Mouth and gut: Stomatitis, diarrhea, and a warning for gastrointestinal perforation.
• Lungs: Interstitial lung disease and pneumonitis.
• Pregnancy: Embryo-fetal toxicity, with the usual counseling that follows that class of warning.

Reuters reported that Revolution Medicines priced Rasonque at $39,800 for a 30-day supply in the United States. RBC Capital Markets, cited in the same dispatch, estimated more than 2,000 patients were already in the expanded-access program and sketched about $28 million in U.S. pancreatic cancer revenue in the third quarter. The company launched a support program, (ON)Path, to help with insurance, financial aid and treatment education. A monthly figure in that range will still decide, in practice, who starts the pill this fall and who waits on a prior authorization.

The American Cancer Society’s current SEER-based figures still give pancreatic cancer a combined five-year relative survival of 13%, and a five-year relative survival of 3% once it has spread, based on people diagnosed from 2015 to 2021. Localized disease is at 44% and regional disease at 17%. About 80% of patients are diagnosed after the cancer has already moved, Revolution Medicines said, which is the setting this approval actually occupies. Median survival of 13.2 months in that setting is a large step from 6.7 months, and it is still measured in months.

A Second Front in Lung Cancer

The same chemistry is already in a global Phase 3 program for metastatic RAS-mutant non-small cell lung cancer. The FDA has granted Breakthrough Therapy designation for adults with previously treated, locally advanced or metastatic NSCLC whose KRAS mutations are not G12C, after platinum chemotherapy and a PD-(L)1 antibody. That is the inverse of the first RAS pills: a label aimed at everyone G12C drugs miss.

Outside the United States the drug remains investigational. The EMA has started a phased review and given it orphan status for pancreatic cancer plus high-priority handling under the Cancer Medicines Pathfinder project. PanCAN’s Anna Berkenblit called the U.S. nod the most significant advance she has seen against the disease and noted that an oral pill is less of a burden than intravenous chemotherapy. Doctors who treat this cancer have said a RAS drug that works will pull a long line of experimental agents behind it. First-line pancreatic trials are part of that line; they are not this label.

The wager that just paid off was specific: skip the G12C niche, glue the on-state protein that pancreatic tumors actually depend on, and take the survival result to FDA on an accelerated clock. The agency answered with a use so wide it does not ask for a mutation test. What the pill does in lung cancer, and in patients who have never had chemotherapy, is the next time that wager gets marked to market.

Frequently Asked Questions

What chemotherapy did RASolute 302 use as the control arm?

Investigators could pick among four cytotoxic regimens that the company said represented standard care across the regions in the trial, rather than a single mandated cocktail. That design is why the FDA described the comparator as physician’s choice of standard-of-care chemotherapy, and why the survival gap is being read as a test against real second-line practice, not against one outdated recipe.

How long do patients stay on the 300 mg daily dose?

The FDA’s recommended dose is 300 mg by mouth once daily until the cancer progresses or the toxicity is no longer acceptable, not for a fixed number of cycles. In RASolute 302, 52% of patients on Rasonque were treated for six months or longer and 2% for more than a year, according to the pooled safety text circulating with the label.

Is daraxonrasib approved for lung cancer?

No. The August 26 approval is limited to metastatic pancreatic adenocarcinoma. The FDA has given Breakthrough Therapy designation for previously treated non-small cell lung cancer with KRAS mutations other than G12C after platinum chemotherapy and PD-(L)1 blockade, and Revolution Medicines said a Phase 3 lung program is underway, so any lung use still has to clear its own trial and review.

Which other regulators sat on the U.S. review?

The FDA ran the file under Project Orbis with Health Canada as a collaborator, while the European Medicines Agency and Japan’s Pharmaceuticals and Medical Devices Agency were official observers. Those agencies can still be reviewing their own applications; daraxonrasib is not approved outside the United States.

Does the label warn about pregnancy?

Yes. Alongside rash, mouth sores, diarrhea, gastrointestinal perforation and interstitial lung disease, the FDA listed embryo-fetal toxicity among the warnings and precautions, which means clinicians are expected to counsel patients who could become pregnant in the same way they do for other drugs in that warning class.

Disclaimer: This article is news reporting and analysis of an FDA approval and the clinical trial behind it, and it is for information only. It is not medical advice, a treatment recommendation, or a substitute for a conversation with a licensed oncologist or other qualified physician about an individual diagnosis. Anyone considering Rasonque, chemotherapy, or a clinical trial should consult their own cancer-care team before acting, including on cost, eligibility, and side effects. Survival figures, prices, trial results, and approval terms reflect the sources cited as of August 27, 2026, and may change as labels, studies, and coverage rules are updated.